Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA NSCLC: Exploratory 8-Year Overall Survival Landmark Update from the ADAURA Trial

Journal of Thoracic Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles